325 related articles for article (PubMed ID: 21729319)
21. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM
Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144
[TBL] [Abstract][Full Text] [Related]
22. Defining the pathway to insulin-like growth factor system targeting in cancer.
Rosenzweig SA; Atreya HS
Biochem Pharmacol; 2010 Oct; 80(8):1115-24. PubMed ID: 20599789
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
24. Can we unlock the potential of IGF-1R inhibition in cancer therapy?
King H; Aleksic T; Haluska P; Macaulay VM
Cancer Treat Rev; 2014 Oct; 40(9):1096-105. PubMed ID: 25123819
[TBL] [Abstract][Full Text] [Related]
25. IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways.
Cai W; Ma Y; Song L; Cao N; Gao J; Zhou S; Tang X
BMC Cancer; 2023 Jan; 23(1):87. PubMed ID: 36698167
[TBL] [Abstract][Full Text] [Related]
26. IGF-1R as an anti-cancer target--trials and tribulations.
Chen HX; Sharon E
Chin J Cancer; 2013 May; 32(5):242-52. PubMed ID: 23601239
[TBL] [Abstract][Full Text] [Related]
27. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer.
Heidegger I; Massoner P; Sampson N; Klocker H
Cancer Lett; 2015 Oct; 367(2):113-21. PubMed ID: 26231734
[TBL] [Abstract][Full Text] [Related]
28. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
Singh P; Alex JM; Bast F
Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
[TBL] [Abstract][Full Text] [Related]
29. Dual sphingosine kinase inhibitor SKI-II enhances sensitivity to 5-fluorouracil in hepatocellular carcinoma cells via suppression of osteopontin and FAK/IGF-1R signalling.
Grbčić P; Tomljanović I; Klobučar M; Kraljević Pavelić S; Lučin K; Sedić M
Biochem Biophys Res Commun; 2017 Jun; 487(4):782-788. PubMed ID: 28433634
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation.
Bodzin AS; Wei Z; Hurtt R; Gu T; Doria C
J Cell Physiol; 2012 Jul; 227(7):2947-52. PubMed ID: 21959795
[TBL] [Abstract][Full Text] [Related]
31. The regulation of proliferation and apoptosis in hepatocellular carcinoma via insulin-like growth factor 1 receptor.
Xu G; Chu J; Shi Y; Huang L; Fu J
Growth Horm IGF Res; 2022 Oct; 66():101499. PubMed ID: 36084573
[TBL] [Abstract][Full Text] [Related]
32. Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma.
Ho HK; Chua BT; Wong W; Lim KS; Teo V; Ong HT; Chen X; Zhang W; Hui KM; Go ML; Ullrich A
Mol Oncol; 2014 Oct; 8(7):1266-77. PubMed ID: 24839937
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
34. Insulin-Like Growth Factor 1 Receptor Drives Hepatocellular Carcinoma Growth and Invasion by Activating Stat3-Midkine-Stat3 Loop.
Bie C; Chen Y; Tang H; Li Q; Zhong L; Peng X; Shi Y; Lin J; Lai J; Wu S; Tang S
Dig Dis Sci; 2022 Feb; 67(2):569-584. PubMed ID: 33559791
[TBL] [Abstract][Full Text] [Related]
35. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response.
Dong J; Demarest SJ; Sereno A; Tamraz S; Langley E; Doern A; Snipas T; Perron K; Joseph I; Glaser SM; Ho SN; Reff ME; Hariharan K
Mol Cancer Ther; 2010 Sep; 9(9):2593-604. PubMed ID: 20716637
[TBL] [Abstract][Full Text] [Related]
36. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.
Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S
Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169
[TBL] [Abstract][Full Text] [Related]
37. Targeting IGF-1R in the treatment of sarcomas: past, present and future.
Kim SY; Wan X; Helman LJ
Bull Cancer; 2009; 96(7):E52-60. PubMed ID: 19617179
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapy of the insulin-like growth factor-1 receptor in cancer.
Paz K; Hadari YR
Comb Chem High Throughput Screen; 2008 Jan; 11(1):62-9. PubMed ID: 18220543
[TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.
Hua H; Kong Q; Yin J; Zhang J; Jiang Y
J Hematol Oncol; 2020 Jun; 13(1):64. PubMed ID: 32493414
[TBL] [Abstract][Full Text] [Related]
40. The insulin-like growth factor (IGF) signaling axis and hepatitis C virus-associated carcinogenesis (review).
Kasprzak A; Adamek A
Int J Oncol; 2012 Dec; 41(6):1919-31. PubMed ID: 23076735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
